Home » Pipeline
Pipeline
October 28, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Cyclo Therapeutics, Inc. | Trappsol Cyclo | Niemann-Pick Disease Type C (NPC) | Phase 1 trial initiated enrolling 12 subjects with NPC age 18 years and older at UCSF Benioff Children’s Hospital in Oakland, CA |
| Adverum Biotechnologies, Inc. | ADVM-022 | wet age-related macular degeneration (wet AMD) | Phase 1 trial initiated enrolling subjects with wet AMD who are responsive to anti-vascular endothelial growth factor (VEGF) treatment at eight sites across the U.S. |
| Cerevel Therapeutics | CVL-231 | schizophrenia | Phase 1b trial initiated enrolling 100 subjects age 18 to 50 |
| Axsome Therapeutics, Inc. | AXS-12 | narcolepsy | Phase 2 trial initiated enrolling 20 subjects at multiple sites |
| ADC Therapeutics SA | ADCT-301 (camidanlumab tesirine) | relapsed or refractory Hodgkin lymphoma (HL) | Phase 2 trial initiated enrolling 100 subjects at multiple sites |
| Aristea Therapeutics | RIST4721 | palmoplantar pustulosis (PPP) | Phase 2a trial initiated |
| HighTide Therapeutics, Inc. | HTD1801 | nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus (T2DM) | Phase 2a trial initiated enrolling 100 subjects with NASH and T2DM at 17 sites in the U.S. |
| MacroGenics, Inc. | margetuximab | HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer | Phase 2/3 trial initiated enrolling subjects with HER2-positive and PD-L1-positive tumors at global sites |
| Myovant Sciences | relugolix combination therapy | endometriosis-associated pain | Phase 3 trial initiated enrolling 600 female subjects ages 18 to 50 at sites in the U.S. |
| Urovant Sciences, Inc. | Vibergron | overactive bladder (OAB) | Phase 3 (part 2) trial initiated enrolling 1,000 male subjects with OAB and benign prostatic hyperplasia (BPH) |
| Odontate Therapeutics, Inc. | tesetaxel | metastatic breast cancer | Phase 3 trial initiated enrolling 600 subjects with HER2 negative, hormone receptor positive metastatic breast cancer |
| FibroGen, Inc. | pamrevlumab | unresectable locally advanced pancreatic cancer (LAPC) | Phase 3 trial initiated enrolling 260 subjects |
| Canon Medical Systems USA, Inc. | Advanced Intelligent Clear-IQ Engine (AiCE) | image reconstruction | 510 (k) clearance granted by the FDA |
| Garwood Medical Devices | BioPrax | knee replacement | Breakthrough Device designation granted by the FDA |
| CorFlow Therapeutics AG | CoFI (CorFlow Controlled Flow Infusion) System | coronary microcirculation after standard stent implantation | Breakthrough Device designation granted by the FDA |
| BerGenBio AS | bemcentinib | acute myeloid leukemia | Fast track designation granted by the FDA |
| Heron Therapeutics, Inc. | CINVANTI (aprepitant) injectable emulsion for intravenous (IV) | prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following both highly emetogenic cancer chemotherapy (HEC) and MEC | sNDA approval granted by the FDA |
| Vertex Pharamceuticals Inc. | Trikafta | cystic fibrosis | Approval granted by the FDA |
| Novartis | Beovu (brolucizumab) | wet age-related macular degeneration | Approval granted by the FDA |
| AstraZeneca | Farxiga (dapagliflozin) | type 2 diabetes | Approval granted by the FDA |
| Alexion Pharmaceuticals, Inc. | ULTOMIRIS (ravulizumab-cwvz) | atypical hemolytic uremic syndrome (aHUS) | Approval granted by the FDA |
| Janssen | Stelara (ustekinumab) | moderately to severely active ulcerative colitis | Approval granted by the FDA |
| Foamix Pharamceuticals, Ltd. | AMZEEQ (minocycline) topical foam, 4% | moderate to severe acne vulgaris | Approval granted by the FDA |
| Eton Pharmaceuticals, Inc. | Biorphen (phenylephrine) | hypotension during anesthesia | Approval granted by the FDA |
